Dyno Therapeutics
The Senior Research Associate at Dyno Therapeutics will support animal studies focused on developing muscle AAV-based capsids by processing tissues, conducting molecular assays, supporting histology workflows, and performing in vitro characterizations. The role involves close collaboration with research scientists, computational biologists, and other team members to generate high‑quality data for gene‑therapy projects.
Headquarters
Watertown, Massachusetts, United States
Company Size
51-200 employees
Founded
2018
Dyno is a biotech company focused on building high-performance genetic technologies to transform patient lives. The company develops advanced gene‑delivery platforms and a platform-driven translational approach to turn engineered genetic tools into therapies. Dyno emphasizes collaboration and partnerships with biopharma to advance development and bring genetic medicines to patients.
Dyno Therapeutics Unveils Best-in-Class Dyno-bn8 AAV Vector for Muscle Gene Therapies, Achieving Therapeutic Delivery With Improved Safety Potential
Nov 11, 2025
Dyno Therapeutics and Trisk Bio partner for strategic manufacture
Nov 12, 2025
Dyno Therapeutics Launches Dyno-yp2, a Top-Performing TfR1-Mediated AAV Capsid, to Further Diversify CNS Delivery Portfolio
Jan 12, 2026
Headquarters
San Francisco, CA
Company Size
201-500 employees
Founded
2018
Industry
Technology
Glassdoor Rating
4.2 / 5
Sarah Johnson
Chief Executive Officer
Michael Chen
Chief Technology Officer
Emily Williams
VP of Engineering
David Rodriguez
VP of Product
Jessica Thompson
Chief Financial Officer
Andrew Park
VP of Sales
View leadership team, funding history,
and employee contacts for Dyno Therapeutics.
Dyno GATC Announces AI Agents, Muscle Capsid, and Manufacturing Partner
Nov 11, 2025